Pembrolizumab
- PDF / 169,734 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 22 Downloads / 131 Views
1 S
Pruritus and worsening erythema: case report A 66-year-old woman developed pruritus and worsening erythema during treatment with pembrolizumab for anorectal squamous cell carcinoma. The woman, who had anorectal squamous cell carcinoma treated with unspecified treatment, was found to have disease recurrence with diffuse pelvic adenopathy 2 years after initial therapy. Therefore, she started receiving pembrolizumab [route and dosage not stated]. However, after initiating the second cycle of the pembrolizumab therapy, she developed worsening erythema and pruritus of the bilateral gluteal folds as well as the buttocks with sloughing of the skin, which were attributed to pembrolizumab [duration of treatment to reactions onsets not stated]. The woman’s pembrolizumab therapy was stopped for 2 months due to worsening of dermatologic complications. Initially, she was treated with unspecified systemic and topical steroids, but she was refractory to the steroid therapy. She was hospitalised for second-line treatment and received received IV naloxone followed by oral naltrexone. Two weeks after naltrexone therapy, she had a near complete resolution of erythema of the gluteal folds, and she did not complaint about pruritus as well. She was discharged from the hospital with planned re-initiation of pembrolizumab with prophylactic naltrexone in order to prevent further dermatological toxicities. Singh R, et al. Naloxone and Maintenance Naltrexone as Novel and Effective Therapies for Immunotherapy-Induced Pruritus: A Case Report and Brief Literature Review. 803504091 Journal of Oncology Practice 15: 347-348, No. 6, 1 Jun 2019. Available from: URL: http://doi.org/10.1200/JOP.18.00797
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
